NanoKTN member wins SET For Britain award
Medal awarded to ThaoNguyen Nguyen for Porphyrin-DNA poster
ThaoNguyen Nguyen was awarded the medal for her poster that looked at the use of Porphyrin-DNA as a scaffold for nanoarchitectures. The poster was judged the best chemistry presentation.
ThaoNguyen’s research focuses on the use of DNA as architecture for Porphyrin chromophore arrays (natural molecules found in heme or chlorophyll) for applications in future nanochips and potentially in photodynamic therapy for cancer treatment. The results show that DNA has great potential for the transformation from being a building block of life to being a building block for nanotechnology.
SET for Britain aims to encourage, support and promote Britain's early-stage and early-career research scientists, engineers and technologists to ensure continued progress in the development of UK research and r&d, and ultimately the future of UK business. The awards give early-career scientists the opportunity to communicate state-of-the-art science to Members of Parliament and scientific peers.
ThaoNguyen’s poster also won the EPSRC Award for Young Scientist at the UK Nano & Emerging Technologies Forum last year, hosted by the Nano Knowledge Transfer Network (NanoKTN) and UK Trade & Investment (UKTI). Being a NanoKTN member and winning the EPSRC Award contributed towards ThaoNguyen’s success at SET for Britain and has had a great impact on promoting her research.
‘Winning the Roscoe Medal and the EPSRC Award has given me opportunities to communicate my research to a broader audience, one that I would not normally expect to meet,’ she said.
‘Embedding an awareness within the next generation of current research will help to strengthen business and hopefully create further connections between academia and industry.’
Established by the Technology Strategy Board, the NanoKTN is managed by Centre for Process Innovation, a technology development and consulting company.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
The path to commercial allogeneic iPSC therapies
The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development
Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies
Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Research & Development
Lonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation
New GS Ori‑Go vector technology supports titers higher than 11 g/L and reliable bulk pool stability, enabling more predictable material generation and shortened cell line development timelines